Dec 8 (Reuters) - The U.S. Food and Drug Administration has qualified the first artificial intelligence tool designed to help ...

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

Mayo Clinic researchers have uncovered how aging "zombie cells" trigger harmful inflammation that accelerates a severe and ...

Mayo Clinic researchers have discovered how aging "zombie cells" contribute to inflammation that speeds up a serious form of ...

The FDA has qualified AI-Based Histologic Measurement of MASH, or AIM-MASH AI Assist — the first AI drug development tool — ...

A groundbreaking AI tool, AIM-NASH, has received FDA approval to revolutionize liver disease drug trials. This innovative ...

The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their ...

Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH treatment plan.

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), a spectrum of liver conditions ranging from simple steatosis to steatohepatitis (MASH), fibrosis, and cirrhosis, represents a global ...

CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on ...